These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35363600)

  • 21. Effect of a single exacerbation on decline in lung function in COPD.
    Halpin DMG; Decramer M; Celli BR; Mueller A; Metzdorf N; Tashkin DP
    Respir Med; 2017 Jul; 128():85-91. PubMed ID: 28610675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measures of bronchodilator response of FEV
    Torén K; Bake B; Olin AC; Engström G; Blomberg A; Vikgren J; Hedner J; Brandberg J; Persson HL; Sköld CM; Rosengren A; Bergström G; Janson C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():973-980. PubMed ID: 28356729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair
    Yildiz P; Bayraktaroglu M; Gorgun D; Secik F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2859-2867. PubMed ID: 27920513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV
    Calverley PMA; Mueller A; Fowler A; Metzdorf N; Wise RA
    Ann Am Thorac Soc; 2018 Feb; 15(2):200-208. PubMed ID: 28957643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Vestbo J; Anderson JA; Brook RD; Calverley PM; Celli BR; Crim C; Martinez F; Yates J; Newby DE;
    Lancet; 2016 Apr; 387(10030):1817-26. PubMed ID: 27203508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.
    Zvizdic F; Begic E; Mujakovic A; Hodzic E; Prnjavorac B; Bedak O; Custovic F; Bradaric H; Durak-Nalbantic A
    Med Arch; 2019 Apr; 73(2):72-75. PubMed ID: 31391690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of FEV
    Yee N; Markovic D; Buhr RG; Fortis S; Arjomandi M; Couper D; Anderson WH; Paine R; Woodruff PG; Han MK; Martinez FJ; Barr RG; Wells JM; Ortega VE; Hoffman EA; Kim V; Drummond MB; Bowler RP; Curtis JL; Cooper CB; Tashkin DP; Barjaktarevic IZ
    Chest; 2022 Apr; 161(4):949-959. PubMed ID: 34767825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characterization and outcomes of impulse oscillometry-defined bronchodilator response: an ECOPD cohort-based study.
    Lu L; Wu F; Peng J; Wu X; Hou X; Zheng Y; Yang H; Deng Z; Dai C; Zhao N; Zhou K; Wan Q; Tang G; Cui J; Yu S; Luo X; Yang C; Chen S; Ran P; Zhou Y
    Respir Res; 2024 Mar; 25(1):149. PubMed ID: 38555433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
    Wang C; Sun T; Huang Y; Humphries M; Bai L; Li L; Wang Q; Kho P; Firth R; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2015; 10():57-68. PubMed ID: 25609940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study.
    Menzies-Gow A; Ambrose CS; Colice G; Hunter G; Cook B; Molfino NA; Llanos JP; Israel E
    Adv Ther; 2023 Nov; 40(11):4957-4971. PubMed ID: 37723356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
    Wedzicha JA; Zhong N; Ichinose M; Humphries M; Fogel R; Thach C; Patalano F; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():339-349. PubMed ID: 28176893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bronchodilator responsiveness and reported respiratory symptoms in an adult population.
    Tan WC; Bourbeau J; Hernandez P; Chapman KR; Cowie R; FitzGerald JM; Aaron S; Marciniuk DD; Maltais F; Buist AS; O'Donnell DE; Sin DD;
    PLoS One; 2013; 8(3):e58932. PubMed ID: 23554960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    JAMA; 2018 Oct; 320(15):1548-1559. PubMed ID: 30326124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of bronchodilator responsiveness in asthma and chronic obstructive pulmonary disease.
    Chhabra SK; Bhatnagar S
    Indian J Chest Dis Allied Sci; 2002; 44(2):91-7. PubMed ID: 12026258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exacerbations and health care resource utilization in patients with airflow limitation diseases attending a primary care setting: the PUMA study.
    Montes de Oca M; Aguirre C; Lopez Varela MV; Laucho-Contreras ME; Casas A; Surmont F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3059-3067. PubMed ID: 27994446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors of acute exacerbation and disease progression in young patients with COPD.
    Bae J; Lee HJ; Choi KY; Lee JK; Park TY; Heo EY; Lee CH; Kim DK; Lee HW
    BMJ Open Respir Res; 2024 Jul; 11(1):. PubMed ID: 39019624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
    Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.